CPRX Catalyst Pharmaceuticals Inc
Price (delayed)
$20.28
Market cap
$2.41B
P/E Ratio
34.37
Dividend/share
N/A
EPS
$0.59
Enterprise value
$2.03B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
Highlights
Catalyst Pharmaceuticals's equity has surged by 62% YoY and by 8% QoQ
Catalyst Pharmaceuticals's gross profit has increased by 45% YoY and by 6% QoQ
Catalyst Pharmaceuticals's net income has decreased by 41% YoY but it has increased by 4.7% QoQ
The stock's P/E is 90% more than its 5-year quarterly average of 17.4 and 35% more than its last 4 quarters average of 24.4
The EPS has declined by 46% year-on-year
Key stats
What are the main financial stats of CPRX
Market
Valuations
Earnings
Shares outstanding
118.69M
Market cap
$2.41B
Enterprise value
$2.03B
Price to earnings (P/E)
34.37
Price to book (P/B)
3.94
Price to sales (P/S)
5.52
EV/EBIT
21.74
EV/EBITDA
15.6
EV/Sales
4.68
Revenue
$434.48M
EBIT
$93.56M
EBITDA
$130.41M
Free cash flow
$196.47M
Per share
Balance sheet
Liquidity
EPS
$0.59
Free cash flow per share
$1.66
Book value per share
$5.15
Revenue per share
$3.68
TBVPS
$4.49
Total assets
$706.36M
Total liabilities
$97.71M
Debt
$2.99M
Equity
$608.66M
Working capital
$382.11M
Debt to equity
0
Current ratio
5.14
Quick ratio
4.69
Net debt/EBITDA
-2.86
Margins
Efficiency
Dividend
EBITDA margin
30%
Gross margin
86.7%
Net margin
15.7%
Operating margin
19.8%
Return on assets
12.2%
Return on equity
14.3%
Return on invested capital
135%
Return on capital employed
15.2%
Return on sales
21.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPRX stock price
How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
4.21%
1 week
2.32%
1 month
5.08%
1 year
56.84%
YTD
20.64%
QTD
30.92%
Financial performance
How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$434.48M
Gross profit
$376.57M
Operating income
$85.88M
Net income
$68.15M
Gross margin
86.7%
Net margin
15.7%
Catalyst Pharmaceuticals's net margin has shrunk by 59% YoY
The operating margin has shrunk by 57% YoY but it rose by 4.2% QoQ
Catalyst Pharmaceuticals's gross profit has increased by 45% YoY and by 6% QoQ
The revenue rose by 43% YoY and by 6% QoQ
Growth
What is Catalyst Pharmaceuticals's growth rate over time
Valuation
What is Catalyst Pharmaceuticals stock price valuation
P/E
34.37
P/B
3.94
P/S
5.52
EV/EBIT
21.74
EV/EBITDA
15.6
EV/Sales
4.68
The stock's P/E is 90% more than its 5-year quarterly average of 17.4 and 35% more than its last 4 quarters average of 24.4
The EPS has declined by 46% year-on-year
Catalyst Pharmaceuticals's equity has surged by 62% YoY and by 8% QoQ
The stock's price to book (P/B) is 5% more than its last 4 quarters average of 3.6 but 3.1% less than its 5-year quarterly average of 3.9
The revenue rose by 43% YoY and by 6% QoQ
The price to sales (P/S) is 26% higher than the last 4 quarters average of 4.2 and 10% higher than the 5-year quarterly average of 4.8
Efficiency
How efficient is Catalyst Pharmaceuticals business performance
The ROIC has dropped by 87% year-on-year
The ROE has plunged by 60% YoY and by 8% from the previous quarter
CPRX's return on assets has dropped by 59% year-on-year and by 8% since the previous quarter
The ROS has dropped by 55% year-on-year but it has increased by 2.4% since the previous quarter
Dividends
What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPRX.
Financial health
How did Catalyst Pharmaceuticals financials performed over time
The total assets has soared by 59% year-on-year and by 9% since the previous quarter
The total liabilities rose by 42% YoY and by 15% QoQ
Catalyst Pharmaceuticals's debt is 100% lower than its equity
CPRX's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
Catalyst Pharmaceuticals's equity has surged by 62% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.